Olanzapine and Aripiprazole in Elderly Patients with Paranoid Delusions
For patients over 65 with paranoid delusions, start olanzapine at 2.5-5 mg/day or aripiprazole at 5 mg/day, with slow upward titration every 3-4 days as tolerated, targeting the minimum effective dose while monitoring closely for metabolic effects, extrapyramidal symptoms, and cardiovascular changes.
Starting Doses
Olanzapine
- Initial dose: 2.5-5 mg/day 1, 2
- The APA guideline explicitly recommends initiating antipsychotics at low doses in elderly patients with dementia and titrating to the minimum effective dose 1
- Expert consensus supports olanzapine 5.0-7.5 mg/day as a therapeutic range for agitated dementia with delusions 3
- FDA labeling confirms olanzapine's efficacy across 10-30 mg/day in adults, but elderly patients require substantially lower doses 2
Aripiprazole (Abilify)
- Initial dose: 5 mg/day 4
- A retrospective study of 52 elderly inpatients found median starting dose of 5 mg with median maximum dose of 10 mg 4
- Expert consensus recommends aripiprazole 15-30 mg/day for late-life schizophrenia, but this applies to chronic schizophrenia rather than isolated paranoid delusions 3
- For elderly patients with paranoid delusions specifically, start lower at 5 mg/day
Titration Schedules
Olanzapine
- Increase by 2.5-5 mg every 3-7 days based on response and tolerability
- Target maintenance dose: 5-10 mg/day for most elderly patients
- The FDA label shows efficacy at 10-20 mg/day in adults, but elderly patients typically respond to lower doses 2
- Avoid exceeding 15 mg/day in elderly unless absolutely necessary
Aripiprazole
- Increase by 5 mg every 3-4 days as tolerated 4
- Mean time to first titration: 3.4 days; mean time to maximum dose: 5 days in elderly inpatients 4
- Target maintenance dose: 10-15 mg/day for elderly patients
- Maximum dose rarely needs to exceed 15 mg/day in this population
Critical Monitoring Parameters
Pre-Treatment Assessment (Both Medications)
Mandatory baseline measurements:
- Weight, BMI, and waist circumference
- Fasting glucose and lipid panel
- Blood pressure and pulse (sitting and standing for orthostasis)
- ECG, especially if cardiovascular risk factors present
- Baseline cognitive assessment
- Movement disorder screening (AIMS or similar)
Olanzapine-Specific Monitoring
Metabolic monitoring is paramount - olanzapine carries the highest metabolic risk among second-generation antipsychotics:
Weeks 1-4:
- Weekly weight and vital signs
- Assess for sedation, falls risk
- Monitor for anticholinergic effects (constipation, urinary retention, confusion)
Week 4:
- Repeat fasting glucose and lipids
- Reassess efficacy - if no response, consider switching 1
Months 2-3:
- Every 2 weeks: weight, blood pressure
- Monthly: fasting glucose
Long-term (every 3 months):
- Weight, waist circumference, BMI
- Fasting glucose and HbA1c
- Lipid panel
- Blood pressure and pulse
- Movement disorder assessment
Common pitfall: Olanzapine causes significant weight gain and metabolic syndrome. In elderly patients with diabetes, dyslipidemia, or obesity, expert consensus recommends avoiding olanzapine entirely 3. Consider aripiprazole instead.
Aripiprazole-Specific Monitoring
Aripiprazole has a more favorable metabolic profile but different concerns:
Weeks 1-4:
Week 4:
- Formal movement disorder assessment
- Efficacy evaluation - if no response, consider dose increase or switch 1
Long-term (every 3 months):
- Weight and metabolic parameters (though risk is lower than olanzapine)
- Movement disorder screening
- Blood pressure and pulse
- Assess for impulse control disorders (rare but reported with dopamine partial agonists)
Cardiovascular Monitoring (Both Medications)
Critical in elderly patients:
- Avoid both medications in patients with QTc prolongation or congestive heart failure if possible 3
- If QTc >450 ms at baseline, obtain cardiology consultation before initiating
- Monitor ECG at week 4 and then every 6 months, or sooner if symptoms develop
- Check orthostatic blood pressure at every visit initially - elderly patients are at high risk for falls
Duration of Treatment
For paranoid delusions in elderly patients:
- If good response achieved, continue for 6 months minimum before considering taper 3
- The APA guideline mandates reassessment at 4 weeks - if no response, taper and discontinue 1
- For delusional disorder specifically, expert consensus suggests 6 months to indefinite treatment at lowest effective dose 3
- Attempt dose reduction at 3-6 months to determine the lowest effective maintenance dose 1
Choosing Between Olanzapine and Aripiprazole
Choose Aripiprazole if patient has:
- Diabetes, pre-diabetes, or metabolic syndrome
- Obesity or significant weight concerns
- Dyslipidemia
- History of poor tolerance to sedating medications
- Parkinson's disease (though quetiapine is preferred) 3
Choose Olanzapine if patient has:
- Severe agitation requiring more sedation
- Failed trial of aripiprazole
- No metabolic risk factors
- History of akathisia with other antipsychotics
Major caveat: Both medications carry FDA black box warnings for increased mortality in elderly patients with dementia-related psychosis. The APA guideline emphasizes that antipsychotics should only be used when symptoms are severe, dangerous, or cause significant distress 1. Document risk-benefit discussion with patient and family before initiating treatment.
Reassessment and Discontinuation
- Quantitative assessment required: Use a validated scale (e.g., BPRS, CGI) to track response 1
- 4-week rule: If no clinically significant response after 4 weeks at adequate dose, taper and withdraw 1
- Taper slowly: Reduce by 25% every 1-2 weeks when discontinuing to avoid withdrawal symptoms
- If side effects emerge: Immediately reassess risk-benefit and consider tapering 1